Open an account

OPKO Health

OPK · NASDAQ

$1.66+$0.05 (+3.11%)TodayMarket closed ·
Prev close $1.61

About OPK

OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. The company is headquartered in Miami, Florida and currently employs 2,275 full-time employees. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.

Employees
2,275
Headquarters
Miami, Florida
Listed
Nov 2, 1995
Sector
Health Care
Industry
Health Care Providers & Services
Website
opko.com

OPK key statistics

Market cap
1.24B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
5.24M
Volume
4.35M
Open price
$1.63
High today
$1.73
Low today
$1.62
52 Week high
$1.77
52 Week low
$0.9769

OPKO Health (OPK) at a glance

As of Oct 20, 2026, OPKO Health (OPK) shares are priced at $1.66, giving the company a market cap of 1.24B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.62 and $1.73. The current price is 2.5% above the day's low and 4.0% below its high.

Volume so far is 4.35M shares, in line with the average of 5.24M shares a day.

Over the past year OPKO Health has ranged from $0.9769 to $1.77, and now sits 86% of the way up that range.

OPKO Health met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.01 per share against an estimate of -$0.0808.

The average analyst price target is $4.93, 197.0% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

50%of 4 analyst ratings say Buy
  • Buy50.0%
  • Hold50.0%
  • Sell0.0%
Price target · 4 analystsAvg $4.93
Low
$3.03
Now
$1.66
High
$8.93

OPK earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 68.7% on average.

  1. Q3 FY24: reported -$0.09 per share against an estimate of -$0.0943
  2. Q4 FY24: reported $0.01 per share against an estimate of -$0.0943
  3. Q1 FY25: reported -$0.10 per share against an estimate of -$0.0693
  4. Q2 FY25: reported -$0.19 per share against an estimate of -$0.1145
  5. Q3 FY25: reported $0.03 per share against an estimate of -$0.0455
  6. Q4 FY25: reported -$0.04 per share against an estimate of -$0.0693
  7. Q1 FY26: reported -$0.07 per share against an estimate of -$0.0707
  8. Q2 FY26: reported -$0.01 per share against an estimate of -$0.0808

OPK news

  • Vandana Singh

    Myriad Genetics Offloads Struggling Prenatal Unit for $210 Million to Labcorp

  • Avi Kapoor

    Crude Oil Moves Higher; Charles Schwab Shares Fall After Q3 Results

  • Vandana Singh

    OPKO Health Sheds Diagnostics Businesses in Major Labcorp Deal

  • Press releasePRNewswire

    Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Avi Kapoor

    Crude Oil Down Over 5%; Boeing Shares Rise After Q2 Results

  • Press releasePRNewswire

    NextPlat Reports Third Quarter 2025 Results

  • Press releasePRNewswire

    Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses

Similar companies

Companies in the same industry as OPKO Health

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.